explore -WSS

explore

author：hotspot 2025-10-02 18:49:14 - browse：944

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： NIH nominee Bertagnolli will get October confirmation hearing

knowledge

hotspot

WSS

WATCH: Why do bright lights make us see spots?

How to protect patients from sexual assault

New weight loss drugs vying to be the next Wegovy or Mounjaro

Amazon on where the company's health care bets are headed next

Long Covid needs a new name — and a new frame

A new House health package & hospitals’ new site

hotspot

explore

hotspot

Jerome Adams on the need for new antivirals for Covid

How to fix cancer clinical trials' diversity problem

Heart attack and stroke risk calculators need revising

AstraZeneca chief proposes a novel edit to the drug pricing bill

DIEP, the 'gold standard' of breast reconstruction, is under threat

How to fix cancer clinical trials' diversity problem

Medical records are filled with copy

Weighted lottery helped low

Activists slam private health insurers over coverage restrictions

How medical schools plan to diversify without affirmative action

entertainment

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

New weight loss drugs vying to be the next Wegovy or Mounjaro

Food makers to regulators: Ultra

Hospitals consider fixing cancer drug shortages on their own

Trump surgeon general acknowledges mistakes during Covid

Ethical issues complicate the benefits of medical crowdfunding

knowledge

focus

hotspot

knowledge